B of A Securities Maintains Buy on ResMed, Lowers Price Target to $230
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Lyanne Harrison maintains a Buy rating on ResMed (NYSE:RMD) but lowers the price target from $250 to $230.
September 18, 2023 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ResMed's price target has been lowered from $250 to $230 by B of A Securities, though the Buy rating is maintained.
The news directly pertains to ResMed as B of A Securities has lowered its price target for the company. However, the maintained Buy rating indicates continued confidence in the company's prospects, which may mitigate any potential negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100